Search
Chikungunya vaccine (live, attenuated)
go.drugbank.com/drugs/DB18701ApprovedInvestigational[L48726] It is approved for use in patients 18 years of age and older who are at high-risk of exposure to chikungunya virus. … In late 2013, the first cases were identified in the Caribbean, and it has since spread to most of the Americas.[L48786] There are no approved treatments for active chikungunya virus infection.
Shark liver oil
go.drugbank.com/drugs/DB11088ApprovedHowever the major component is considered to be squalene, which may range up to 90% of the shark oil, depending on the species. … Shark oil is extracted from the livers of sharks, which can account for up to 25% of their total body weight.
Mixtures: Care One Hemorrhoidal, Care One HemorrhoidalDolutegravir
go.drugbank.com/drugs/DB08930ApprovedInvestigational[A7514] The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. … [L1035] On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named
Florbetapir F-18
go.drugbank.com/drugs/DB09149ApprovedInvestigationalwho are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. … Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide
Ixekizumab
go.drugbank.com/drugs/DB11569ApprovedInvestigationalIt is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. … Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons
Berdazimer
go.drugbank.com/drugs/DB18712ApprovedIt is one of the 5 most prevalent skin diseases in the world and the third-most common viral skin infection in children. … It releases NO through exposure to proton donors like water, which will degrade the N-diazeniumdiolate entity.
Trimebutine
go.drugbank.com/drugs/DB09089ApprovedInvestigationalIt is used to restore normal bowel function and is commonly present in pharmaceutical mixtures as trimebutine maleate salt form. … It is marketed for the treatment of irritable bowel syndrome (IBS) and lower gastrointestinal tract motility disorders, with IBS being one of the most common multifactorial GI disorders [A19691].
Ceftazidime
go.drugbank.com/drugs/DB00438ApprovedInvestigational[L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of
Products: CEFTAZIDIMA DOC GENERICI, CEFTAZIDIMA MYLAN GENERICSCupric oxide
go.drugbank.com/drugs/DB11134ApprovedCupric oxide poses potential health and environmental concern due to toxic and mutagenic particles generating reactive oxygen species [A32656].
Mixtures: Se-Natal One, One Tablet Daily Mens FormulaVericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigationalcell types) that catalyze the synthesis of cyclic guanosine monophosphate (cGMP) in response to activation by nitric oxide (NO). … to its structure have dramatically decreased its susceptibility to oxidative metabolism,[A227458] resulting in a relatively long half-life and allowing for once-daily dosing.